Nano-based Drug Delivery System for Treating Triple-negative Breast Cancer (TNBC)

Jiayi Lu

doi:10.54097/9fx0rm54

Authors

Jiayi Lu

DOI:

https://doi.org/10.54097/9fx0rm54

Keywords:

Breast cancer; Triple-negative breast cancer (TNBC); Nanoparticle; Drug delivery; Cancer treatment.

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited treatment options, primarily due to the lack of hormone receptors and HER2 expression. Nano-based drug delivery systems, including PEGylated liposomes, polymeric nanoparticles, and gold nanoparticles, present a promising strategy to enhance therapeutic outcomes by improving drug solubility, targeting tumor cells more effectively, and reducing systemic toxicity. These nanoparticles utilize both passive and active targeting mechanisms to address TNBC’s resistance to conventional therapies. This paper reviews the underlying mechanisms, challenges, and current clinical trials of nano-based drug delivery systems for TNBC treatment, emphasizing their role in improving treatment effectiveness and patient results.

Downloads

Download data is not yet available.

References

[1] World Health Organization. Breast cancer. World Health Organization. 2024. https://www.who.int/news-room/fact-sheets/detail/breast-cancer

[2] National Breast Cancer Foundation. Breast cancer facts & stats 2024. National Breast Cancer Foundation. 2024. https://www.nationalbreastcancer.org/breast-cancer-facts

[3] Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., Davidson, R., Eccles, D., Cole, T., Cook, J., Brewer, C., Tischkowitz, M., Douglas, F., Hodgson, S., Walker, L., … Easton, D. F. Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. Journal of the National Cancer Institute, 2013, 105(11), 812–822.

[4] Derakhshan, F., & Reis-Filho, J. S. Pathogenesis of triple-negative breast cancer. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 181-204.

[5] Lehmann, B. D., Jovanović, B., Chen, X., et al. Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLOS ONE, 2016, 11(6), e0157368.

[6] Burstein, M. D., Tsimelzon, A., Poage, G. M., et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research, 2015, 21(7), 1688-1698.

[7] Liu, S., & Wicha, M. S. Targeting breast cancer stem cells. Journal of Clinical Oncology, 2010, 28(25), 4006-4012.

[8] Brooks, M. D., Burness, M. L., & Wicha, M. S. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell, 2015, 17(3), 260-271.

[9] Su, S., Chen, J., Yao, H., Liu, J., Yu, S., et al. CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell, 2018, 172(6), 841-856.

[10] Meacham, C. E., & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature, 2013, 501(7467), 328-337.

[11] Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell, 2009, 139(5), 871-890.

[12] Takebe, N., Ivy, S. P., Contessa, J., Rahib, L., & Lee, J. K. Targeting cancer stem cells by targeting the tumor microenvironment. Clinical Cancer Research, 2019, 25(10), 2800-2806.

[13] Huang, P., Wang, X., Liang, X., Yang, J., Zhang, C., & Kong, D. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. Acta Biomaterialia, 2019, 85, 1-26.

[14] Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications, 2018, 9(1410), 1-11.

[15] Jain, R. K., Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology, 2010, 7, 653–664.

[16] Chowdhury, S. R., Khan, I., & Dutta, R. Bioactive nanotherapeutic trends to combat triple-negative breast cancer. Frontiers in Oncology, 2021, 11, 654901.

[17] Akter, M., Cui, H., & Shi, X. Gold nanoparticles in triple-negative breast cancer therapeutics. Bioactive Materials, 2023, 17, 61-76.

[18] Kong, D., Wang, Z., & Liang, X. Nanoparticle drug delivery systems and their applications as targeted therapies for triple-negative breast cancer. Pharmacological Research, 2023, 187, 106552.

[19] Song, G., Wu, H., Zhang, X., et al. Polymeric micelle-based paclitaxel for the treatment of triple-negative breast cancer. Journal of Drug Delivery Science and Technology, 2020, 57, 101724.

[20] Wang, F., Song, W., Zhou, Q., & Chen, Y. Nanoparticle formulation of cisplatin for cancer therapy. Drug Delivery, 2016, 23(1), 1374-1381.

[21] BIND Therapeutics, Inc. (2014). BIND-014 nanoparticle drug conjugate. Clinical trial data. Retrieved from https://www.bindtherapeutics.com

[22] Xu, H., Zhao, G., Zhang, X., et al. DNA-damaging nanoliposomes in preclinical models of triple-negative breast cancer. Nanomedicine, 2019, 18(3), 512-523.